DexCom, Inc. reported second quarter 2026 financial results on July 30, 2026, announcing revenue of $1.308 billion, a 13% year-over-year increase. GAAP operating income rose to $318.3 million (24.3% margin), while diluted net income per share reached $0.64. The company raised its full-year 2026 revenue guidance midpoint to $5.18–$5.25 billion and increased margins for Non-GAAP Gross Profit, Operating Income, and Adjusted EBITDA. Strategic highlights included positive results from the CONNECT trial for type 2 diabetes patients not using insulin and the launch of a reimagined Stelo app experience. DexCom operates in the medical device industry, specializing in continuous glucose monitoring (CGM) systems and biosensing technology for diabetes management.
